Brain Metastases
345
76
110
93
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
37 trials with published results (11%)
Research Maturity
93 completed trials (27% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.1%
35 terminated out of 345 trials
72.7%
-13.9% vs benchmark
7%
24 trials in Phase 3/4
40%
37 of 93 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 93 completed trials
Clinical Trials (345)
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Pembrolizumab In Central Nervous System Metastases
Use of AlignRT System During Stereotactic Radiosurgery
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
Phase I Study of Fractionated Stereotactic Radiation Therapy
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
REMASTer: REcurrent Brain Metastases After SRS Trial
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain